Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADVAX: Pembrolizumab + Radiotherapy in Metastatic Cancers
NCT02303990Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in metastatic cancer, melanoma, non-small cell lung cancer (NSCLC) and 2 more, sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 2 years. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
metastatic cancermelanomanon-small cell lung cancer (NSCLC)breast cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02303990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303990.